Immuno-Biological Laboratories Co Ltd
TSE:4570
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Immuno-Biological Laboratories Co Ltd
Net Issuance of Debt
Immuno-Biological Laboratories Co Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immuno-Biological Laboratories Co Ltd
TSE:4570
|
Net Issuance of Debt
-¥7.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
35%
|
CAGR 10-Years
22%
|
|
|
Carna Biosciences Inc
TSE:4572
|
Net Issuance of Debt
¥612.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
28%
|
|
|
S
|
Shin Nippon Biomedical Laboratories Ltd
TSE:2395
|
Net Issuance of Debt
¥2.6B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Medinet Co Ltd
TSE:2370
|
Net Issuance of Debt
-¥781k
|
CAGR 3-Years
39%
|
CAGR 5-Years
48%
|
CAGR 10-Years
34%
|
|
|
CellSource Co Ltd
TSE:4880
|
Net Issuance of Debt
¥159.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
DNA Chip Research Inc
TSE:2397
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Immuno-Biological Laboratories Co Ltd
Glance View
Immuno-Biological Laboratories Co., Ltd. engages in the manufacture and sale of antibody-related reagents and pharmaceutical products. The company is headquartered in Fujioka-Shi, Gumma-Ken(Gunma-Ken) and currently employs 65 full-time employees. The company went IPO on 2007-03-02. The firm operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.
See Also
What is Immuno-Biological Laboratories Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
-7.5m
JPY
Based on the financial report for Dec 31, 2025, Immuno-Biological Laboratories Co Ltd's Net Issuance of Debt amounts to -7.5m JPY.
What is Immuno-Biological Laboratories Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 10Y
22%
Over the last year, the Net Issuance of Debt growth was 82%.
